Rula

Azova Inc.

Azova Inc. runs a HIPAA-compliant digital health marketplace that connects patients with pharmacists, physicians, dietitians, and labs for on-demand consultations, at-home lab kits, and compounded GLP-1, skincare, and menopause therapies. Most services are priced à-la-carte in the mid-range—$39–$99 for consultations, $79–$299 for lab kits, and $299–$549 monthly for compounded medications—sold exclusively through azova.com and its white-label employer portals. The company’s differentiator is a “cloud pharmacy” model: prescribers, compounders, and CLIA-certified labs share one EHR so a patient can chat with a doctor, receive a customized medication, and schedule follow-up labs without leaving the platform. Azova also supplies the telehealth engine behind several national pharmacy chains and insurers, giving it reach far beyond its consumer site. Core buyers are 25-55-year-old insured professionals, many in rural or suburban markets, who want GLP-1 weight-loss, fertility, or skincare protocols without in-office visits. They value data privacy, transparent pricing, and the ability to manage family care from one dashboard. Azova competes with direct-to-consumer pill-and-kit brands and large telehealth networks by integrating pharmacy, lab, and care teams in a single workflow, offering true continuity rather than one-off prescriptions. Its B2B licensing of the same platform creates a dual revenue stream that funds faster medication innovation and nationwide clinician coverage.

Your entire health team, one app, zero waiting rooms

Trimrx

Trimrx is an online-only direct-to-consumer brand that sells compounded GLP-1 weight-loss injections—primarily semaglutide and tirzepatide—along with telehealth consultations, starter supply kits, and monthly refill plans. All medications are prescribed and fulfilled through the company’s U.S.-partnered pharmacies; no insurance is required. Pricing sits in the mid-range tier: starter programs open at roughly $299 and monthly refills run $399–$499, placing the brand below most in-clinic peptide clinics but above budget pill-based alternatives. The company’s core promise is “prescription GLP-1 in 48 hours”: patients complete an asynchronous intake, a state-licensed clinician reviews within one business day, and medication ships overnight from an affiliated pharmacy. Doses are customized to the nearest 0.1 mg, vials arrive in temperature-controlled packaging with pre-loaded syringes, and unlimited dosage adjustments are included. Trimrx markets itself as the fastest, most transparent tele-GLP-1 option, publishing real-time pharmacy inventory and batch-level Certificates of Analysis online. Trimrx targets busy professionals aged 25-55 who want clinically proven weight-loss injectables without clinic visits, insurance hurdles, or brand-name mark-ups. Customers value speed, privacy, and data—many track body-composition metrics and share progress in the brand’s private Slack community. The aesthetic is clean, medical-minimalist, appealing to consumers who already subscribe to DTC services for hair, skin, or hormone care. Competitors include other telehealth platforms offering compounded semaglutide, cash-pay medical spas, and traditional pharmacies. Trimrx differentiates through faster fulfillment (48-hour average), flat monthly pricing that covers all clinician touchpoints, and public lot-level testing—practices not universally offered by rival tele-GPL-1 sites.

GLP-1 in 48 hours, transparent dosing, no clinic visits required

Gemiini

Gemiini sells subscription-based video therapy for learners with autism, Down syndrome, speech delay, and other developmental needs. Plans run $98–$248 per month, placing the brand in the mid-range tele-therapy segment. All purchases and delivery are handled online; there is no physical retail. The service is built on clinician-developed “discreet video modeling” clips that break language, social, and life skills into 5- to 10-second loops viewable on any device. A cloud dashboard lets parents or therapists assign custom playlists and track data, while a mobile app allows offline viewing. The model is cited in peer-reviewed journals and used by school districts in three countries. Primary buyers are parents of children aged 18 months–12 years who want evidence-based speech and reading support they can implement at home without weekly clinic visits. The brand appeals to families who value data-driven, affordable therapy that fits into daily routines such as meals, car rides, or classroom centers. Gemiini competes with in-person speech clinics, tabletop card systems, and generalized educational-video libraries. It differentiates by offering a research-backed video protocol, unlimited home replay, progress analytics, and insurance-reimbursable subscriptions, eliminating travel time and reducing per-session cost to under $3.

Therapy that fits your life, not your schedule

Ivim Health

Ivim Health is a telemedicine platform that prescribes and ships GLP-1 receptor agonist weight-loss medications (semaglutide and tirzepatide) and complementary metabolic-support supplements. All care is delivered online through a $129–$149 monthly membership that includes provider consults, unlimited messaging, and free 2-day pharmacy shipping; the drugs themselves are billed separately and priced at or below typical retail pharmacy levels. The company operates only through its website—no physical clinics—and accepts HSA/FSA cards but not insurance for the membership fee. The brand’s core promise is “MD-led weight loss in 24 hr”: patients complete an intake, receive same-day provider review, and—if medically eligible—have medication dispatched from Ivim’s partnered sterile compounding pharmacies. Ivim formulates its own flavored sublingual and injection kits, advertises transparent batch testing, and provides a mobile dashboard that syncs with smart scales to track BMI, visceral fat, and glucose trends. Its most visible offering is the “QuickStart GLP-1 Trio,” a four-week introductory pack that bundles titrated semaglutide, B12 shots, and craving-control lozenges. Typical customers are U.S. adults 25-55 with BMI ≥27 who want clinical-grade obesity treatment without long waitlists or insurance hurdles; many are busy professionals, post-partum women, and remote workers already comfortable with subscription services. They value speed, privacy, and data-driven feedback, and they prefer a cash-pay model that keeps treatment off employer health records. Ivim competes with national telehealth weight-loss programs, cash-pay clinic chains, and compound pharmacies that market directly on social media. It differentiates by integrating prescription issuance, in-house drug manufacturing, and biometric tracking inside one vertically controlled platform, promising faster fulfillment (24 hr vs. 3-7 days) and tighter clinical oversight (MDs, not nurse pools) than most low-cost rivals while staying cheaper than concierge metabolic clinics.

Weight loss that actually keeps up with your life

Kuurehealth

Kuurehealth sells wearable therapeutic devices that combine transcutaneous electrical nerve stimulation (TENS), heat therapy, and red-light therapy to relieve chronic and acute pain. The line-up centers on three cordless, app-controlled wraps—neck, knee, and lumbar—priced between $149 and $199, situating the brand in the mid-range wellness-tech segment. All sales flow through kuurehealth.com and Amazon storefronts; no brick-and-mortar distribution is listed. The brand’s core differentiator is “triple-modality” pain relief delivered in a single, lightweight wrap that can be worn while working or driving; each unit pairs with a smartphone app offering preset and custom treatment protocols. Kuurehealth promotes drug-free recovery, FDA-cleared components, and a 30-day “feel-better” guarantee, positioning itself as tech-enabled self-care rather than a conventional medical device. Primary buyers are 25-55-year-old desk workers, recreational athletes, and post-surgery patients seeking non-pharmaceutical pain management that fits an on-the-go lifestyle. The messaging emphasizes autonomy, data-driven wellness, and avoidance of opioids or frequent clinic visits, aligning with values of convenience, body hacking, and long-term health ownership. Kuurehealth competes in the crowded portable therapy hardware space against generic TENS pads, heated braces, and subscription-based recovery apps. It differentiates by integrating all three modalities into one sleek wrap, backing efficacy with small-scale clinical data, and offering lifetime app updates—moving the purchase from a one-time commodity to an evolving wellness platform.

Pain relief that moves with you, no pills required

Done.

Done sells FDA-approved stimulant and non-stimulant medications for ADHD, prescribed and managed through its telehealth platform. The service is priced at a mid-range level: an initial psychiatric evaluation is $199, follow-up visits are $99, and medications are filled at standard pharmacy copays or cash prices. Sales and care delivery are 100 % online; patients complete intake, book video appointments, and receive e-prescriptions sent to local pharmacies. The brand’s core promise is same-week access to licensed ADHD specialists who can titrate and refill controlled substances without in-person visits. Done automates reminders, 24-hour provider messaging, and seamless pharmacy integration, positioning itself as a faster alternative to traditional psychiatric waitlists. Its best-known offering is the monthly membership that includes unlimited dosage adjustments and prior-authorization support. Target customers are 18-45-year-old adults who suspect or have confirmed ADHD and want convenient, stigma-free pharmacologic treatment. They value speed, digital convenience, and continuity of care over therapy add-ons. Many are students, remote workers, or entrepreneurs who see medication optimization as a productivity lever. Done competes with both brick-and-mortar psychiatry practices and emerging tele-mental-health platforms. It differentiates by focusing narrowly on ADHD medication management rather than broad therapy bundles, guaranteeing sub-seven-day appointment availability, and maintaining a clinician network licensed to prescribe Schedule II controlled substances nationwide.

Your ADHD diagnosis and prescription, approved and delivered this week

Forhers

Forhers is a direct-to-consumer telehealth platform focused on prescription and over-the-counter women’s wellness. Core categories include birth control (from $12/mo), dermatology (topical and oral acne, anti-aging, hair-loss formulas $20-$65/mo), sexual health (Valacyclovir, emergency contraception $17-$90), and daily supplements for libido, sleep, and menopause ($15-$49). All care is delivered online through asynchronous physician consults (included in price) and automatic home delivery; no physical retail. The brand’s clinical model lets patients complete a text-based intake and receive same-day prescribing in 40+ states, eliminating office visits and insurance paperwork. Hers is notable for bundling multiple conditions—skin, hair, mental health—into one $10-30/mo subscription after a single $39 medical consult fee. Its private-label oral minoxidil, spironolactone, and customized topical blends are frequently cited in media as accessible alternatives to in-office prescriptions. Primary customers are U.S. women 18-44 who want discreet, time-saving access to stigmatized or recurring prescriptions. They value transparent flat pricing, HIPAA-secure messaging, and the ability to pause shipments anytime; many first seek acne or hair-loss help, then add birth control or antidepressants within the same dashboard. Hers competes with other telehealth startups and legacy brick-and-mortar clinics that require appointments or insurance. It differentiates through women-only positioning, bundling multiple therapeutic areas under one subscription, aggressive price transparency, and vertically integrated mail-order pharmacy that ships within 2-3 days nationwide.

Your prescription, your timeline, your privacy, all from home